Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Minder neoadjuvante therapie bij rectumcarcinoom door selectie op basis van MRI-criteria?
jul 2019 | Maag-darm-leveroncologie